Literature DB >> 29208774

Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer.

Iñaki Comino-Mendez1, Nicholas Turner2,3.   

Abstract

<b/> Advances in circulating tumor DNA (ctDNA) analysis are revealing new treatment strategies for patients with cancer. Detection of residual disease with ctDNA analysis predicts relapse with high accuracy after treatment for early-stage lung cancer. Cancer Discov; 7(12); 1368-70. ©2017 AACRSee related article by Chaudhuri et al., p. 1394. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29208774     DOI： 10.1158/2159-8290.CD-17-1086

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  6 in total

1.  In the literature: February 2018.

Authors:  Andrés Cervantes
Journal:  ESMO Open       Date:  2018-02-01

Review 2.  The emerging role of cell-free DNA as a molecular marker for cancer management.

Authors:  Abel Jacobus Bronkhorst; Vida Ungerer; Stefan Holdenrieder
Journal:  Biomol Detect Quantif       Date:  2019-03-18

Review 3.  Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.

Authors:  Gaurav Nepal; Mahika Khurana; Domenica Herrera Bucheli; Siddhartha Bhandari; Utsav Joshi; Riwaj Bhagat; Jessica Holly Rehrig; Prasun Pudasainee; Yow Ka Shing; Juan Fernando Ortiz; Rajeev Ojha; Bikram Prasad Gajurel; Jonathan Quinonez; Samir Ruxmohan; Trevine Albert; Steven Licata; Joel Stien
Journal:  Neurol Int       Date:  2022-01-11

4.  A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.

Authors:  Yun Hu; Sébastien Paris; Hampartsoum Barsoumian; Chike O Abana; Kewen He; Duygu Sezen; Mark Wasley; Fatemeh Masrorpour; Dawei Chen; Liangpeng Yang; Joe D Dunn; Saumil Gandhi; Quynh-Nhu Nguyen; Maria Angelica Cortez; James W Welsh
Journal:  J Nanobiotechnology       Date:  2021-12-11       Impact factor: 10.435

5.  Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.

Authors:  A Rose Brannon; Gowtham Jayakumaran; Monica Diosdado; Juber Patel; Anna Razumova; Yu Hu; Fanli Meng; Mohammad Haque; Justyna Sadowska; Brian J Murphy; Tessara Baldi; Ian Johnson; Ryan Ptashkin; Maysun Hasan; Preethi Srinivasan; Anoop Balakrishnan Rema; Ivelise Rijo; Aaron Agarunov; Helen Won; Dilmi Perera; David N Brown; Aliaksandra Samoila; Xiaohong Jing; Erika Gedvilaite; Julie L Yang; Dennis P Stephens; Jenna-Marie Dix; Nicole DeGroat; Khedoudja Nafa; Aijazuddin Syed; Alan Li; Emily S Lebow; Anita S Bowman; Donna C Ferguson; Ying Liu; Douglas A Mata; Rohit Sharma; Soo-Ryum Yang; Tejus Bale; Jamal K Benhamida; Jason C Chang; Snjezana Dogan; Meera R Hameed; Jaclyn F Hechtman; Christine Moung; Dara S Ross; Efsevia Vakiani; Chad M Vanderbilt; JinJuan Yao; Pedram Razavi; Lillian M Smyth; Sarat Chandarlapaty; Gopa Iyer; Wassim Abida; James J Harding; Benjamin Krantz; Eileen O'Reilly; Helena A Yu; Bob T Li; Charles M Rudin; Luis Diaz; David B Solit; Maria E Arcila; Marc Ladanyi; Brian Loomis; Dana Tsui; Michael F Berger; Ahmet Zehir; Ryma Benayed
Journal:  Nat Commun       Date:  2021-06-18       Impact factor: 17.694

Review 6.  Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model.

Authors:  Chang Yang; Bai-Rong Xia; Wei-Lin Jin; Ge Lou
Journal:  Cancer Cell Int       Date:  2019-12-18       Impact factor: 5.722
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.